Having a solid understanding of the heartworm life cycle, and the damage this disease can do, is the first step in getting pet owners on the right track with treatment.
Killing worms stops the progression of disease, but they don't go away. That's why it's important that veterinary clients understand that some of those problems are permanent. (PixieMe/stock.adobe.com)
Heartworm disease can be a complex topic for both practitioners and veterinary clients to understand, according to Brian Herrin, DVM, PhD, an assistant professor at Kansas State University College of Veterinary Medicine. Through his work as a parasitologist at the Kansas State Veterinary Diagnostic Laboratory, Dr. Herrin has noticed shifting dynamics in heartworm infection and management that are presenting new challenges for practitioners. He spoke about heartworm disease in detail at Fetch dvm360 conference in Baltimore, including the fundamentals of this ubiquitous disease.
An appropriate understanding of heartworm disease relies on knowledge of the Dirofilaria immitis life cycle:
Infection transitions from prepatent to patent at six to seven months PI, once mature adults begin to produce microfilariae. From this point forward, antigen tests are capable of detecting heartworm infection.
Most veterinarians understand that heartworm disease is a multiorgan condition affecting the heart, lungs and vessels; however, it's important to remember that antigen-antibody complexes formed by the patient's immune response can also cause glomerulonephritis and polyarthropathies. The overall severity of disease depends on multiple factors, including worm burden, patient size, level of immune response and duration of infection.
Although “probably the most common presentation [at diagnosis] is a happy Lab wagging its tail,” Dr. Herrin explained that appearances can be deceiving.
“If there is a positive test,” he continued, “[the patient has] heartworm disease and needs to be treated. Do not wait for clinical signs to occur before initiating treatment.”
Unpublished experimental studies have shown that significant vessel damage can occur as early as 152 days after infection from a burden of only three worms. Such findings serve as a reminder that severe disease begins before antigen tests can even detect heartworm infection around day 180 PI.
Heartworm-induced vasculitis is progressive, which is why treatment should begin promptly after diagnosis. Infection can eventually cause thromboembolic disease and small vessel damage, the latter of which remains poorly understood. When worms die either naturally or with treatment, the fragments travel through the circulation before lodging in small vessels, resulting in embolic disease. Although recovery is possible after an acute embolic episode, the small vessel damage is a lifelong effect of heartworm infection that is difficult to treat and causes lasting pathology. Large worm burdens may overwhelm the body's ability to break down the thrombi and recanalize vessels. In these cases, the clots typically fibrose in an attempt to wall off the worm fragments. Mummified worms can remain for life and have been found at necropsy, even more than a decade after treatment.
Talking to owners about heartworm disease is “really challenging,” Dr. Herrin admitted. Proper communication at diagnosis is essential for ensuring that owners adhere to recommended treatment. It's imperative that owners understand that some of the pathologic changes associated with heartworm disease can't be reversed.
“Killing worms stops the progression of disease, but they don't go away,” he emphasized, which is why it's important that owners understand “some of those problems are permanent.”
Dr. Stilwell received her DVM from Auburn University, followed by a MS in fisheries and aquatic sciences and a PhD in veterinary medical sciences from the University of Florida. She provides freelance medical writing and aquatic veterinary consulting services through her business, Seastar Communications and Consulting.
Oral solution approved by the FDA for canine heart failure
November 22nd 2024Vetmedin Solution from Boehringer Ingelheim is indicated for treatment of cases caused by myxomatous mitral valve disease or dilated cardiomyopathy and is the first oral solution approved by the FDA for this use in dogs
Read More